All In Biotech

Free tool

FAERS Monitor: Movantik

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 204760 or its brand name (Movantik, Naloxegol Oxalate). Reports on generic versions are filed under their own applications.

Reports

3,970

Serious

1,878

47% of reports

Hospitalization

908

Death reported

288

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea386
  • constipation384
  • drug ineffective377
  • pain367
  • nausea332
  • off label use275
  • abdominal pain264
  • abdominal pain upper229
  • intentional product misuse224
  • vomiting210
  • death188
  • fatigue187
  • headache187
  • hyperhidrosis185
  • malaise176

Reports by year received

View as table
YearReports
20102
20112
20121
20134
20142
2015371
2016675
2017575
2018352
2019300
2020254
2021263
2022235
2023235
2024254
2025271
2026174

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,189 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intentional product misuseSignal22413.612.02,604
constipationSignal3849.38.52,877
hyperhidrosisSignal1857.66.61,062
abdominal painSignal2646.05.41,111
abdominal pain upperSignal2295.95.2935
diarrhoeaSignal3863.22.9589
painSignal3673.22.9558
vomitingSignal2102.42.1168
nauseaSignal3322.22.0231
malaiseSignal1762.11.8106
off label use2751.71.575
headache1871.61.440
drug ineffective3771.51.470
fatigue1871.31.111
death1881.21.04

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.